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Abstract
Background The transforming growth factor (TGF)-β
superfamily comprises cytokines such as TGF-β and Bone
Morphogenetic Proteins (BMPs), which have a critical role
in a multitude of biological processes. In breast cancer, high
levels of TGF-β are associated with poor outcome, whereas
inhibition of TGF-β-signaling reduces metastasis. In contrast,
B M P - 7i n h i b i t sb o n em e t a s t a s i so fb r e a s tc a n c e rc e l l s .
Methods Inthisstudy,weinvestigatedtheeffectofBMP-7on
TGF-β-induced invasion in a 3 dimensional invasion assay.
Results BMP-7 inhibited TGF-β-induced invasion of the
metastatic breast cancer cell line MCF10CA1a, but not of
its premalignant precursor MCF10AT in a spheroid invasion
model. The inhibitoryeffect appears to be specific for BMP-7,
as its closest homolog, BMP-6, did not alter the invasion of
MCF10CA1aspheroids.Toelucidatethemechanismbywhich
BMP-7 inhibits TGF-β-induced invasion, we analyzed
invasion-related genes. BMP-7 inhibited TGF-β-induced
expression of integrin αvβ3 in the spheroids. Moreover,
targeting of integrins by a chemical inhibitor or knockdown
of integrin β3 negatively affected TGF-β-induced invasion.
On the other hand, overexpression of integrin β3 counteracted
the inhibitory effect of BMP7 on TGF-β-induced invasion.
Conclusion Thus, BMP-7 may exert anti-invasive actions




ALK Activin receptor-like kinase
BMP Bone Morphogenetic Protein




Smad Sma and Mad related gene product
TGF-β Transforming growth factor-β
1 Introduction
Breast cancer is one of the major causes of death in women.
However, most mortality and morbidity does not arise from
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morbidity is especially caused by bone metastasis. In order
to metastasize a cancer cell must shed many of its epithelial
characteristics, invade the surrounding tissue to enter the
circulation, subsequently survive in the circulation, extrav-
asate and proliferate in the metastatic niche [1]. Invasion is
therefore a key step in the metastatic cascade. Several
classes of proteins have been shown to play a role in this
process, such as the integrin family of adhesion receptors.
Integrins, which consist of an α and β subunit, are
important for adhesion of cells to the extracellular matrix
[2]. Cancer cells express specific integrin combinations,
whose signaling favors migration and invasion [3]. Integrin
αvβ3 is strongly expressed by breast cancer cells, especially
by cells residing in bone metastasis [4]. Its expression
promotes bone metastasis of breast cancer cells [5, 6],
whereas inhibition of αvβ3 diminishes their osteotropism
[7].
Transforming Growth Factor (TGF)-β has a dual role in
carcinogenesis. In the early stages it has a growth inhibitory
and pro-apoptotic effect, whereas at the later stages of
cancer, TGF-β promotes invasion and metastasis [8, 9]. In
line with its stimulatory role in cancer progression, TGF-β
is frequently overexpressed in breast cancer and its
expression correlates with poor prognosis and metastasis
[10–12]. Moreover, studies in mouse models have demon-
strated that inhibition of TGF-β-signaling in breast cancer
cells reduces metastasis [13–16].
TGF-β and Bone Morphogenetic Proteins (BMPs) signal
via comparable mechanisms. Upon binding of the ligand,
the type II receptor phosphorylates the type I receptor. The
type I receptor, in turn, phosphorylates the receptor-
regulated (R)- Sma and Mad related gene product (Smad).
Phosphorylated R-Smads form heteromeric complexes with
the common mediator Smad (Co-Smad) Smad4. These
complexes then translocate to the nucleus, where they
regulate transcription of target genes in collaboration with
other transcription factors [17]. In most cell types, TGF-β
signals through the TGF-β receptor type II (TβRII) and the
TGF-β type I receptor, also termed activin receptor-like
kinase 5 (ALK5). ALK5 mediates the phosphorylation of
Smad2 and Smad3 [18]. BMPs signal through their specific
BMP receptor type II (BMPRII) and BMP type I receptors
(BMPRI) which induce the activation of Smad1, Smad5
and Smad8 [19]. In addition to the previously described
Smad pathways, receptor activation results in activation of
several other non-Smad signaling pathways, for example
Mitogen Activated Protein Kinase (MAPK) pathways [20].
TGF-β is thought to be pro-invasive by inducing
epithelial-to-mesenchymal transition (EMT). During this
process, carcinoma cells acquire a more motile, mesenchy-
mal phenotype [21]. In normal breast and kidney epithelial
cells BMP-7 can inhibit TGF-β-induced EMT [22]; BMP-7
has also been shown to inhibit EMT and bone metastasis in
breast and prostate tumors [23, 24]. However, the effect of
BMP-7 on tumor invasion is unknown.
P r e v i o u s l y ,w eh a v es e tu pas p h e r o i di n v a s i o nm o d e l
to study TGF-β-induced invasion [25, 26]. In this assay,
spheroids made from MCF10A series of cell lines invade
in response to TGF-β. The MCF10A cell lines originate
from MCF10A1, a spontaneously immortalized breast cell
line [27]. This cell line was transformed with oncogenic
RAS, resulting in MCF10AT (hereafter referred to as M-
II), which forms premalignant lesions in mice that upon
grafting progressed into carcinoma [28]. From these
carcinomas MCF10CA1a was isolated (hereafter referred
to as M-IV), which metastatasizes to the lung [29]. Using
these cell lines in the invasion assay, we have shown the
importance of Smad signaling for TGF-β-induced inva-
sion [25]. In the current paper, we have analyzed the role
of BMP-7. We show that BMP-7 can inhibit TGF-β-
induced invasion through inhibition of TGF-β-induced
integrin β3 expression.
2 Materials and methods
2.1 Cell culture
MCF10AT (M-II) and MCF10CA1a (M-IV) were obtained
from Dr. Fred Miller (Barbara Ann Karmanos Cancer
Institute, Detroit, USA) and maintained as described [25].
2.2 Invasion spheroid assays
The invasion spheroid assay was performed essentially as
described in [25]. Briefly, 10
3 cells were allowed to form
spheroids and spheroids were embedded in a 1:1 collagen:
methocel mixture onto a collagen coated plate. Recombi-
nant human TGF-β3 (a generous gift of Dr. K. Iwata, OSI
Pharmaceuticals, Inc, New York, USA), BMP-6, BMP-7
(both a kind gift of K. Sampath, Creative Biomolecules,
Inc, Hoptinton, USA), isotype control antibody (Santa
Cruz) or human BMP-7 neutralizing antibody (R&D
Systems) were added directly into the collagen:methocel
mixture at 4°C. After 30 min incubation at 37°C medium
was added on top of the collagen, either containing no
solvent, DMSO or the integrin inhibitor GLPG0187
(Galapagos NV, Mechelen, Belgium). Invasion was moni-
tored during the next 2 days and quantified by measuring
the area using ImageJ or Adobe Photoshop.
2.3 Western blot analysis
2×10
5 cells were seeded onto a six well plate and 1 day
later starved for 16 h in medium containing 2.5% horse
20 H.P.H. Naber et al.serum (Gibco), 10 ng/ml epidermal growth factor (EGF)
(Upstate), 50 ng/ml cholera toxin (Calbiochem), 0.25 μg/ml
hydrocortisone (Sigma), 5 μg/ml insulin (Sigma), 100 U/ml
penicillin and 50 μg/ml streptomycin (Gibco). After starva-
tion,cellswerestimulated,washedandlysedinRIPAbufferor
sample buffer. Lysates were subjected to SDS-PAGE &
Western blotting. Phosphorylation of Smad1/5/8 was detected
by anti phospho-Smad1 antibody as described before [30].
Phospho-Smad2 antibody was purchased from Cell Signal-
ing. Total Smad1 antibody was from Zymed.
2.4 Transcriptional reporter assay
1×10
5 cells were seeded onto a 24-well plate and 1 day later
transfected for 4 h with the reporters CAGA12-Luc [31]o r
BRE-Luc [32] using either Lipofectamine 2000 or LTX
(Invitrogen). An expression plasmid for β-galactosidase was
co-transfected and used to correct for transfection efficiency.
One day after transfection, cells were serum starved
overnight in medium containing 2.5% horse serum (Gibco),
10 ng/ml epidermal growth factor (EGF) (Upstate), 50 ng/ml
cholera toxin (Calbiochem), 0.25 μg/ml hydrocortisone
(Sigma), 5 μg/ml insulin (Sigma), 100 U/ml penicillin and
50 μg/ml streptomycin (Gibco) and subsequently stimulated
for 8 h. Luciferase and β-galactosidase activity were
determined as previously described [31]. Each transfection
was carried out in triplicate and representative experiments
are shown.
2.5 RNA isolation, cDNA synthesis and quantitative PCR
RNA isolation, cDNA synthesis and quantitative PCR (Q-
PCR) were performed as previously described [25]. The
following primers were used: acidic ribosomal phosphopro-
tein (ARP) forward 5′- CACCATTGAAATCCTGAGT
GATGT -3′ and reverse 5′- TGACCAGCCGAAAGGA
GAAG -3′; matrix metalloproteinase 2 (MMP2) forward 5′-
AGATGCCTGGAATGCCAT-3′ and reverse 5′-
GGTTCTCCAGCTTCAGGTAAT-3′;i n t e g r i nαv forward
5′-CAGGCTTGCAACCCATTCTT-3′ and reverse 5′-
GAATGTGAGCCTGTCGACTAATGTT-3′;i n t e g r i nβ3 for-
ward 5′-ACCTGCTTGCCCATGTTTG-3′ and reverse 5′-
GCGGGTCACCTGGTCAGTTA-3′. All samples were ana-
lyzed in duplicate for each primer set. Gene expression levels
were determined with the comparative ΔCt method using
ARP as reference and the non-stimulated condition was set to
1. Relative expression levels are presented as mean ± S.D.
2.6 Lentiviral transduction
Constructs TRCN0000003234,TRCN0000003235,
TRCN0000003236 and TRCN0000003237 from the Mission
library (Sigma) were used to target integrin β3 with construct
SHC001 as a negative control. Cells were transduced in the
presence of 4 μg/ml polybrene (Sigma) overnight. After
recovery cells were selected and maintained in growth
medium containing 0.5 μg/ml puromycin. For overexpres-
sion of integrin β3, M-IV cells were transduced with a
lentiviral integrin β3 expression construct [33], kindly
provided by Dr. Deborah Novack, Washington University,
St. Louis, USA.
2.7 Statistical analysis
All results are expressed as the mean ± S.D. Statistical
differences were examined by one-way ANOVA followed
by Bonferroni’s multiple comparison test. P<0.05 was
considered as statistically significant.
3 Results
3.1 BMP-7 inhibits TGF-β-induced invasion
in the metastatic cell line M-IV, but not in the premalignant
M-II cell line
BMP-7 inhibits TGF-β-induced EMT of both normal
breast cells [22], as well as of invasive, osteotropic breast
and prostate cancer cells, which is associated with
inhibition of bone metastasis [23, 24]. To investigate
whether BMP-7 also has an inhibitory effect on TGF-β-
induced invasion, we analysed its effect on M-IV in a
spheroid invasion assay. The response of this metastatic
cell line was compared to a precursor cell line, the RAS-
transformed cell line M-II and not M-I, since RAS has
been reported to enhance TGF-β-induced responses [34].
In the absence of TGF-β BMP-7 had no inhibitory effect
on the invasion of M-II and M-IV cells, while TGF-β
induced invasion of both cell types (Fig. 1a–d). However,
BMP-7 strongly inhibited the TGF-β- induced invasion of
the metastatic M-IV cells, but not of the premalignant M-
II cells (Fig. 1a–d). This suggests that BMP-7 specifically
inhibits TGF-β pro-invasive mechanisms exploited by
metastatic cells.
3.2 BMP-7 does not affect proliferation in M-IV cells
To rule out that the observed effects of BMP-7 on TGF-β-
induced invasion are due to effects on cell growth, we
performed proliferation assays. As reported previously [25],
TGF-β has a minor growth-inhibitory effect on M-IV. BMP-
7 on its own did not affect cell proliferation (Supplementary
Figure 1). BMP-7 also did not affect TGF-β-induced
growth inhibition. Thus, the inhibitory effect of BMP-7 on
TGF-β-induced invasion is not due to effects on the growth
of these cells.
BMP-7 Inhibits TGF-β-Induced Invasion of Breast Cancer Cells 21Fig. 1 BMP-7, but not BMP-6, inhibits TGF-β-induced invasion in
M-IV, but not in M-II. a–d Spheroids were allowed to invade collagen
in the presence of BMP-7 (100 ng/ml), TGF-β (5 ng/ml) or TGF-β &
BMP-7. a Pictures of representative spheroids of M-II. b Quantifica-
tion of invasion of M-II experiments shown in (a). c Pictures of
representative spheroids of M-IV. d Quantification of invasion of M-IV
experiments shown in (c). e Spheroids of M-IV were allowed to invade
collagen in the presence of BMP-6 (100 ng/ml), TGFβ (5 ng/ml) or
TGF-β & BMP-6. Pictures of representative spheroids are shown. f
Quantification of invasion of experiments shown in (e). The results
are expressed as mean ± S.D. of at least three spheroids per condition.
One representative out of three independent experiments is shown.
Significance *** p<0.001
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invasion in M-IV
To assess whether other BMPs are capable of inhibiting
TGF-β-induced invasion, we studied the effect of BMP-6,
which is the closest homolog of BMP-7 and shares 73%
identity on the amino acid level. In contrast to BMP-7,
BMP-6 did not affect the TGF-β-induced invasion of M-IV
cells, and also did not inhibit basal invasion. (Fig. 1e, f).
These data indicate that the ability of BMP-7 to inhibit
TGF-β-induced invasion is specific for BMP-7.
3.4 Noggin induces invasion in M-IV through blocking
of BMP-7
Previous studies of our group have shown that the basal
invasion of M-IV cells is dependent on TGF-β-signaling [25].
However we did not observe an inhibitory effect of BMP-7
addition on the basal invasion (Fig. 1c, d). One explanation
for this might be that BMP-7 is already present at saturating
levels under these conditions. Indeed, we found that M-IV
cells express BMP-7 mRNA and that the horse serum used in
the assays contained BMP-7 protein (data not shown).
Therefore, we tested the effect of a natural antagonist of
BMP-2, 4 and 7, Noggin. As shown in Fig. 2a and b, Noggin
enhanced basal invasion 2.0-fold in M-IV. In the M-II cell line,
in which TGF-β-induced invasion is not affected by BMP-7,
addition of Noggin also had no effect on basal invasion
(Supplementary Figure 2). Thus, inhibition of BMP-2, 4 and 7
induces invasion in M-IV cells, but not in M-II cells.
Since NoggininhibitsBMP-2,4and7,wenextdetermined
if blockade of BMP-7 can also induce basal invasion of M-IV
cells. For this, we added BMP-7 neutralizing antibodies to the
spheroid invasion system. These antibodies enhanced basal
invasion1.8-foldcomparedtothecontrolantibody(Fig.2c, d).
This indicates that the induction of invasion by Noggin is
mainly due to inhibition of BMP-7. Moreover, it suggests that
TGF-β and BMP-7 also antagonize each other under basal
conditions.
3.5 Both BMP-6 and BMP-7 induce Smad signaling
Next, we asked whether if the different effects of BMP-6
and BMP-7 on TGF-β-induced invasion in M-IV cells
could be due to the possibility that BMP-7 is more potent in
inducing BMP-signaling than BMP-6. To examine this, we
analyzed activation of BMP-Smad signaling by two means.
First, we analyzed whether BMP-6 and BMP-7 differ in
their ability to induce phosphorylation of Smad1. However,
Western blot analysis showed that Smad1 phosphorylation
is induced to the same extent by both BMPs in M-IV cells,
whereas the total levels of Smad1 were not affected
(Fig. 3a). Second, we investigated transcriptional activation
of BMP-Smads, by using a luciferase-reporter driven by
BMP Responsive Elements (BRE) [32]. Both BMP-6 and
BMP-7 were found to activate the reporter ∼30 fold and
thus efficiently induced BMP-Smad transcriptional activity
in M-IV cells (Fig. 3b). Taken together, these results
indicate that BMP-6 and BMP-7 do not differ in their
ability to induce Smad signaling in this cell line.
3.6 BMP-7 does not affect TGF-β-induced Smad signaling
To investigate the molecular mechanism by which BMP-7
inhibits TGF-β-induced invasion, we analyzed the effects
of BMP-7 and BMP-6 on TGF-β Smad signaling. First, we
analyzed whether BMP-7 had an inhibitory effect on the
Fig. 2 Noggin enhances basal invasion through inhibition of BMP-7.
Spheroids of M-IV were allowed to invade collagen in the absence or
presence of Noggin (200 ng/ml). a Pictures of representative
spheroids. b Quantification of spheroids of experiments shown in
(a). c Spheroids of M-IV were allowed to invade into collagen in the
presence of control antibody or BMP-7 blocking antibody (2 μg/ml).
Representative pictures are shown. d Quantification of spheroids of
experiments shown in (c). The results are expressed as mean ± S.D. of
at least four spheroids per condition. One representative out of three
independent experiments is shown. Significance *** p<0.001
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BMP-6did not affectTGF-β-inducedSmad2phosphorylation
(Fig. 3a). Second, we studied the effect of BMP-7 on TGF-
β-induced Smad3 transcriptional activity. To this end, we
used a luciferase reporter containing 12 repeats of the Smad3
binding sequence CAGA [31]. TGF-β induced the activity
of this reporter ∼55-fold, but both BMP-7 and BMP6 did not
significantly affect the TGF-β-induced reporter activity
(Fig. 3c). Thus, BMP-7 has no effect on TGF-β-induced
Smad signaling in M-IV cells.
3.7 BMP-7 inhibits TGFβ-induced integrin αvβ3
expression
We next examined the effect of BMP-7 on the expression of
TGF-β target genes involved in invasion. As we previously
identified a critical role for matrix metalloproteinase 2
(MMP2) in TGF-β-induced invasion [25], we first analyzed
if TGF-β-induced MMP2 expression is affected by BMP-7
in the spheroid model system. BMP-6 stimulation served as
a negative control. However, as shown in Fig. 4a, BMP-7
(and BMP-6) did not affect TGF-β-induced expression of
MMP2 in M-IV spheroids in collagen. Since integrin αvβ3
has recently been shown to enhance TGF-β-induced EMT
and inhibition of integrin αvβ3 reduces metastasis [7], we
subsequently examined the expression of integrin αv and
β3. Importantly, TGF-β potently induced the expression of
both subunits in the collagen-embedded spheroids, and
BMP-7, but not BMP-6, inhibited the TGF-β-induced
expression of both αv and β3 (Fig. 4b and c). Also, BMP-
7 did not inhibit TGF-β-induced integrin αv and β3
expression in M-II (Supplementary Figure 3a, b). Thus,
the inhibitory action of BMP-7 on TGF-β-induced collagen
invasion of M-IV spheroids might be mediated through
inhibition of TGF-β-induced integrin αvβ3 expression.
3.8 Integrin β3 is necessary for TGF-β-induced invasion
To determine if integrin αvβ3 is important for TGF-β-induced
invasion, we investigated if inhibition of αv integrins blocks
TGF-β-induced invasion in the spheroid model system. For
this, we used a non-peptide integrin inhibitor, GLPG0187.
This molecule exhibits high affinitiy for αvβ1, αvβ3, αvβ5,
αvβ6, αvβ8 as well as α5β1 in in vitro competitive binding
assays (Supplementary Table 1). Treatment of M-IV sphe-
roids with GLPG0187 inhibited TGF-β-induced invasion
(Fig. 5a, b). This indicates that integrin αvβ3 could be
necessary for TGF-β-induced invasion of M-IV cells.
To further establish if integrin β3 is necessary for TGF-β-
induced invasion, we performed RNAi-mediated knockdown
experiments. M-IV cells were transduced with viruses
encoding 4 different shRNA constructs against integrin β3.
These constructs inhibited TGF-β-induced integrin β3
expression at the mRNA level (Supplementary Figure 4a).
TGF-β-induced invasion was indeed inhibited by knockdown
of integrin β3 (Fig. 5c,d), indicating that downregulation of
integrin β3 by BMP-7 contributes to BMP-7-mediated
inhibition of invasion.
Fig. 3 BMP-6 and BMP-7 induce BMP-Smad signaling, but do not
affect TGF-β Smad signaling. a Cells were treated with the indicated
ligands (BMP-6 and BMP-7 at 100 ng/ml, TGF-β at 5 ng/ml) for
15 min, lysed and subjected to SDS-PAGE and Western blotting. Blots
were incubated with phospho-Smad2, phospho-Smad1 and Smad1
antibodies. Total ERK was used as a loading control. b Cells were
transfected with the BRE-Luc reporter construct, starved and
subsequently stimulated for 8 h with BMP-6 or 7 (both at 100 ng/ml).
Relative luciferase activity (RLU) is expressed as mean ± S.D. of
triplicate cultures. c Cells were transfected with the CAGA12-Luc
reporter construct, starved and subsequently stimulated for 8 h with the
indicated ligands (BMP-6 and BMP-7 at 100 ng/ml, TGF-β at 5 ng/ml).
Relative luciferase activity (RLU) is expressed as mean ± S.D. of
triplicate cultures. One representative out of at least three independent
experiments is shown
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invasion from BMP-7 inhibition
To demonstrate that the inhibition of integrin β3 expression by
BMP-7 is critical for the inhibition of TGF-β-induced
invasion, we used a lentiviral vector that overexpresses integrin
β3 [33]. As shown in Supplementary Figure 4b, M-IV cells
transduced with this virus exhibit higher levels of integrin β3
protein compared to wildtype (WT) cells. The overexpression
of integrin β3 did not affect TGF-β-induced invasion, but
completely counteracted the BMP-7 inhibitory effect (Fig. 6).
Taken together, these data suggest that BMP-7 inhibits TGF-β-
i n d u c e di n v a s i o nb yi n h i b i t i n gT G F - β-induced integrin β3
expression.
4 Discussion
In order to understand how BMP-7 exerts its anti-
metastatic effects reported before [23, 24], we investigat-
ed whether BMP-7 interferes with TGF-β-induced inva-
sion of human breast cancer cells. We showed that BMP-7
inhibits TGF-β-induced invasion in the metastatic breast
cancer cell line M-IV through inhibition of integrin β3
expression. In addition, we showed that BMP-7 specifi-
cally inhibits the invasion of this metastatic cell line, and
not the invasion of its premalignant precursor, M-II.
Moreover, the inhibitory effect was specific for BMP-7,
as its closest homolog, BMP-6 did not have any effect on
TGF-β-induced invasion. To our knowledge, this is the
f i r s tr e p o r tt h a ts h o w st h a tB M P - 7i n h i b i t sT G F - β-induced
invasion.
Since the antagonism between TGF-β and BMP-7 has
been described before [22–24, 35–37], the question arises
whether the process that we describe occurs in other cell
types as well. BMP-7 inhibits bone metastasis of the
MDA-MB231 breast cancer cell line [23]a n dP C 3
prostate cancer cell line [24]. However, in these cell lines
BMP-7 inhibited TGF-β/Smad signaling [23, 24], whereas
under our experimental conditions we did not observe an
inhibitory effect of BMP-7 on the TGF-β-Smad pathway.
On the other hand, BMP-7 inhibited tumor progression of
the uveal melanoma cell line OCM-1 without inhibiting
the TGF-β-Smad pathway [37]. Thus, BMP-7 is able to
inhibit the tumor-promoting effects of TGF-β through either
Smad- and non-Smad- mechanisms, depending on the
cellular context.
Our data indicate that the inhibitory effect of BMP-7 on
breast cancer invasion in part can be explained by
inhibition of TGF-β-induced expression of integrin β3.
Integrin β3 is induced by TGF-β and enhances EMT in a
feed-forward loop by inducing Src [38]. It is therefore
tempting to speculate that the inhibition of TGF-β-induced
integrin β3 expression by BMP-7 might also play a role in
the observed antagonistic effects between TGF-β and
BMP-7 in EMT.
As mentioned before we did not detect a significant
effect of BMP-7 on TGF-β Smad signaling, although we
have shown that TGF-β-induced invasion is dependent on
Smad3 and Smad4 [25]. Since TGF-β-induced integrin β3
Fig. 4 BMP-7 inhibits integrin αvβ3 expression, but does not affect
MMP2 expression in M-IV. Spheroids were embedded with BMP-6
(100 ng/ml), BMP-7 (100 ng/ml), TGF-β (5 ng/ml), TGF-β & BMP-6
or TGF-β & BMP-7 for 24 h. MMP2 (a), integrin αv (b)a n d
integrin β3 (c) mRNA expression was analyzed by Q-PCR . One
representative out of three independent experiments is shown.
Significance *** p<0.001 * p<0.05
BMP-7 Inhibits TGF-β-Induced Invasion of Breast Cancer Cells 25expression has been reported to be dependent on p38, but
not on Smads [39], the inhibitory effect of BMP-7 on TGF-
β-induced invasion might be mediated via non-Smad
pathways. However, we could not find a significant effect
of BMP-7 on (TGF-β-induced) p38 phosphorylation that
could explain the inhibition of BMP-7 on TGF-β-induced
integrin β3 expression (data not shown). It is therefore
likely that the effect is mainly due to BMP-7 transcriptional
targets, such as transcription factors or microRNAs, that
interfere with TGF-β-induced integrin β3 expression.
Fig. 5 Integrin αvβ3 is neces-
sary for TGF-β-induced inva-
sion. a Spheroids were allowed
to invade into collagen in the
presence of DMSO or
GLPG0187 (80 nM) with or
without TGF-β (5 ng/ml) Rep-
resentative pictures of spheroids
are shown. b Quantification of
experiment shown in (a). c Cells
were transduced with lentivirus
encoding shRNA against integ-
rin β3 and control lentivirus..
Spheroids of these cells were
allowed to invade in the absence
or presence of TGF-β (5 ng/ml).
Representative pictures of sphe-
roids are shown. d Quantifica-
tion of invasion shown in (c). At
least four spheroids per condi-
tion. were quantified. One rep-
resentative out of three
independent experiments is
shown. Significance ** p<0.01
Fig. 6 Integrin β3 overexpres-
sion rescues TGF-β-induced in-
vasion from BMP-7 inhibition.
Cells were transduced with len-
tivirus containing an integrin β3
overexpression construct. Integ-
rin β3 overexpressing cells or
wildtype (WT) cells were
allowed to invade in BMP-7
(100 ng/ml), TGF-β (5 ng/ml)
or TGF-β & BMP-7. a Repre-
sentative pictures of spheroids
are shown. b Quantification of
spheroid experiment shown in
(a). The results are expressed as
mean ± S.D. of at least four
spheroids per condition. One
representative out of three inde-
pendent experiments is shown.
Significance ** p<0.01 NS not
significant
26 H.P.H. Naber et al.One striking finding is that BMP-7 is able to inhibit TGF-
β-induced invasion, whereas BMP-6 is not, despite the fact
thattheyshare73%aminoacidhomologyandare abletobind
to the same receptors [40–43]. Generally, BMP-6 is regarded
as more potent than BMP-7 in inducing bone differentiation
[40, 44, 45]. However, BMP-7 is inhibited by Noggin,
whereas BMP-6 is resistant to inhibition by Noggin due to
an additional lysine at residue 60 [45]. On the other hand, we
found that BMP-6 and BMP-7 induce Smad1 phosphoryla-
tion and BMP-Smad transcriptional activity to the same
extent in MIV cells. Possibly, BMP-6 or BMP-7 have
different effects on non-Smad signaling pathways. However,
we did not observe any significant differences between
BMP-7 and BMP-6 on (TGF-β-induced) p38 and ERK
phosphorylation in MIV cells (data not shown).
BMP-7 did not inhibit TGF-β-induced invasion of the
premalignant precursor cell line M-II. Interestingly, over-
expression of a dominant-negative TGF-β-receptor also
had differential effects on these two cell lines in vivo [46].
It is likely that upon tumor progression the response to
TGF-β is altered in such a manner that BMP-7 is able to
inhibit certain TGF-β responses. On the genetic level M-IV
has an extra copy of the long arm of chromosome 1, a type
of alteration often observed in breast cancer [29]. A detailed
survey of the genetic changes in the MCF10A series of cell
lines revealed several genetic changes in M-IV compared to
M-II, as well as differences in global gene expression [47].
It is likely that the ability of BMP-7 to inhibit TGF-β-
induced invasion is highly dependent on these additional
genetic changes.
In conclusion, we have shown that BMP-7 inhibits TGF-
β-induced invasion through inhibition of TGF-β-mediated
integrin β3 expression. These data reinforce the rationale to
either use BMP-7 or target integrin β3 in breast cancer
metastasis.
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